WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 574740
CAS#: 114084-78-5
Description: Ibandronic Acid is a bisphosphonate anti-resorptive agent and bone resorption inhibitor.
MedKoo Cat#: 574740
Name: Ibandronic Acid
CAS#: 114084-78-5
Chemical Formula: C9H23NO7P2
Exact Mass: 319.095
Molecular Weight: 319.2305
Elemental Analysis: C, 33.86; H, 7.26; N, 4.39; O, 35.08; P, 19.41
Synonym: Ibandronic Acid; BPH 24; Ibandronate
IUPAC/Chemical Name: P,P'-[1-Hydroxy-3-(methylpentylamino)propylidene]bisphosphonic Acid
InChi Key: MPBVHIBUJCELCL-UHFFFAOYSA-N
InChi Code: InChI=1S/C9H23NO7P2/c1-3-4-5-7-10(2)8-6-9(11,18(12,13)14)19(15,16)17/h11H,3-8H2,1-2H3,(H2,12,13,14)(H2,15,16,17)
SMILES Code: CCCCCN(CCC(P(O)(O)=O)(P(O)(O)=O)O)C
Appearance: Solid powder
Purity: >95% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >3 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
| Biological target: | Ibandronic acid is a highly potent nitrogen-containing bisphosphonate used for the treatment of osteoporosis. |
| In vitro activity: | In lines with western blot, the results of autophagy flux and TEM assay further confirmed that autophagy, occurred in Ang II + IBAN group, was higher than that in the untreated and Ang II or IBAN-treated groups (Fig. 2B, C). Therefore, these findings demonstrated that IBAN promoted autophagy in Ang II-treated HUVECs and human pulmonary microvascular endothelial cells (HPMECs). Reference: Cell Death Discov. 2022 Apr 9;8(1):186. https://pubmed.ncbi.nlm.nih.gov/35397636/ |
| In vivo activity: | Administration of IBN (ibandronate) at 1 μg/kg (IBN_1) was insufficient for the suppression of bone loss and morphological change in trabeculae; however, administration of 3 μg/kg (IBN_3) and 10 μg/kg (IBN_10) significantly suppressed the osteoporotic changes induced by estrogen deficiency. Reference: Calcif Tissue Int. 2022 Jun;110(6):736-745. https://pubmed.ncbi.nlm.nih.gov/34989822/ |
The following data is based on the product molecular weight 319.2305 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
| Formulation protocol: | 1. Han J, Yang J, Wang Q, Yin X, Sun Z, Huang C, Chen G, Zheng L, Jiang D. Ibandronate promotes autophagy by inhibiting Rac1-mTOR signaling pathway in vitro and in vivo. Cell Death Discov. 2022 Apr 9;8(1):186. doi: 10.1038/s41420-022-00995-6. PMID: 35397636; PMCID: PMC8994753. 2. Lotz EM, Cohen DJ, Ellis RA, Wayne JS, Schwartz Z, Boyan BD. Ibandronate Treatment Before and After Implant Insertion Impairs Osseointegration in Aged Rats with Ovariectomy Induced Osteoporosis. JBMR Plus. 2019 Mar 6;3(7):e10184. doi: 10.1002/jbm4.10184. PMID: 31372590; PMCID: PMC6659452. 3. Ishimoto T, Saito M, Ozasa R, Matsumoto Y, Nakano T. Ibandronate Suppresses Changes in Apatite Orientation and Young's Modulus Caused by Estrogen Deficiency in Rat Vertebrae. Calcif Tissue Int. 2022 Jun;110(6):736-745. doi: 10.1007/s00223-021-00940-2. Epub 2022 Jan 6. PMID: 34989822; PMCID: PMC9108105. 4. Takeda S, Sakai S, Tanaka K, Tomizawa H, Serizawa K, Yogo K, Urayama K, Hashimoto J, Endo K, Matsumoto Y. Intermittent Ibandronate Maintains Bone Mass, Bone Structure, and Biomechanical Strength of Trabecular and Cortical Bone After Discontinuation of Parathyroid Hormone Treatment in Ovariectomized Rats. Calcif Tissue Int. 2017 Jul;101(1):65-74. doi: 10.1007/s00223-017-0255-6. Epub 2017 Feb 28. PMID: 28246925; PMCID: PMC5486915. |
| In vitro protocol: | 1. Han J, Yang J, Wang Q, Yin X, Sun Z, Huang C, Chen G, Zheng L, Jiang D. Ibandronate promotes autophagy by inhibiting Rac1-mTOR signaling pathway in vitro and in vivo. Cell Death Discov. 2022 Apr 9;8(1):186. doi: 10.1038/s41420-022-00995-6. PMID: 35397636; PMCID: PMC8994753. 2. Lotz EM, Cohen DJ, Ellis RA, Wayne JS, Schwartz Z, Boyan BD. Ibandronate Treatment Before and After Implant Insertion Impairs Osseointegration in Aged Rats with Ovariectomy Induced Osteoporosis. JBMR Plus. 2019 Mar 6;3(7):e10184. doi: 10.1002/jbm4.10184. PMID: 31372590; PMCID: PMC6659452. |
| In vivo protocol: | 1. Ishimoto T, Saito M, Ozasa R, Matsumoto Y, Nakano T. Ibandronate Suppresses Changes in Apatite Orientation and Young's Modulus Caused by Estrogen Deficiency in Rat Vertebrae. Calcif Tissue Int. 2022 Jun;110(6):736-745. doi: 10.1007/s00223-021-00940-2. Epub 2022 Jan 6. PMID: 34989822; PMCID: PMC9108105. 2. Takeda S, Sakai S, Tanaka K, Tomizawa H, Serizawa K, Yogo K, Urayama K, Hashimoto J, Endo K, Matsumoto Y. Intermittent Ibandronate Maintains Bone Mass, Bone Structure, and Biomechanical Strength of Trabecular and Cortical Bone After Discontinuation of Parathyroid Hormone Treatment in Ovariectomized Rats. Calcif Tissue Int. 2017 Jul;101(1):65-74. doi: 10.1007/s00223-017-0255-6. Epub 2017 Feb 28. PMID: 28246925; PMCID: PMC5486915. |
1. McCormack PL, Plosker GL. Ibandronic acid: a review of its use in the treatment of bone metastases of breast cancer. Drugs. 2006;66(5):711-728. doi:10.2165/00003495-200666050-00011
2. Barrett-Lee P, Casbard A, Abraham J, et al. Oral ibandronic acid versus intravenous zoledronic acid in treatment of bone metastases from breast cancer: a randomised, open label, non-inferiority phase 3 trial [published correction appears in Lancet Oncol. 2014 Feb;15(2):e52-3]. Lancet Oncol. 2014;15(1):114-122. doi:10.1016/S1470-2045(13)70539-4
